No PFS, OS Benefit Seen in Final Results from PACIFIC-2

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations

CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date